Federica Tomao is an Associate Professor at the Department of Maternal, Child and Urological Sciences within Sapienza University of Rome. She actively teaches and supervises courses in Medicine and Surgery , Nursing , and Midwifery programs across multiple institutions. Current faculty member with academic rank Teaching roles in 6th, 3rd, and 2nd year courses Specialized in gynecologic oncology Research Focus : Her work spans ovarian cancer, breast cancer, and endometrial cancer, emphasizing chemotherapy optimization, precision medicine, and radiomics. Notably, she contributes to understanding PARP inhibitors, immune checkpoint therapies, and fertility preservation techniques in cancer survivors. Recent Publications highlight advancements in sarcopenia analysis, BRCA testing, and radiogenomic nomograms. These studies demonstrate her commitment to bridging imaging and molecular data for improved cancer management. Email : federica.tomao@uniroma1.it
State University of New York at BuffaloUnited States
Youngjae You is a Professor of Empire Innovation in the Department of Pharmaceutical Sciences at the University at Buffalo School of Pharmacy. His research focuses on Antibody-Drug Conjugates, Cancer Chemotherapy, Medicinal Chemistry, and Targeted Drug Delivery. He holds adjunct roles at the University of Oklahoma Health Sciences Center and has led numerous grants totaling over $10 million in funding. Key awards include the 2019 Professor of Empire Innovation title and multiple DoD/CDMRP grants. His work emphasizes prodrug design, photodynamic therapy, and combination therapies. Education : PhD in Pharmaceutical Chemistry, Chungnam National University (2001) MS in Pharmaceutical Chemistry, Chungnam National University (2000) BPharm, Chungnam National University (1994) Research Interests : Dr. You specializes in developing light-activatable prodrugs for targeted cancer therapies, including far-red/NIR light-activated delivery systems. His work integrates quantitative pharmacokinetic modeling, singlet oxygen dynamics, and receptor-targeted drug conjugation to enhance therapeutic efficacy while minimizing off-target effects. Key applications include bladder, breast, and ovarian cancers. Funding Highlights : NIH/NIGMS: $1.37M (2023-2027) for light-responsive drug delivery National Cancer Institute: $2.1M (2022-2027) for bladder cancer treatments DoD/CDMRP/PRCRP: $392K (2017-2020) for photodynamic-chemotherapy combinations Awards : PHF Presidential Professorship (2018) American Cancer Society Research Scholar Grant (2013) Multiple DoD/CDMRP Idea Awards Service & Grants : Serves as Principal Investigator on 8 major grants. Active reviewer for Wellcome Trust, NIH, and international funding agencies. Holds patents on BODIPY derivatives and singlet oxygen-labile linkers. Lab & Collaborations : Leads the You Lab at UB, collaborating with bioengineers and clinicians to advance photomedicine and targeted drug delivery systems. Engaged in multidisciplinary teams addressing spatiotemporal control in cancer treatments.
Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.
Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Professor Nicholas Buckley is a leading academic in Clinical Pharmacology at the University of Sydney and holds a Visiting Professor position at the University of Peradeniya, Sri Lanka. He serves as Research Director for the South Asian Clinical Toxicology Research Collaboration (SACTRC) and is a Consultant Clinical Pharmacologist & Toxicologist at the NSW Poisons Information Centre and Royal Prince Alfred Hospital. His work focuses on improving clinical toxicology practices, poison control policies, and understanding mechanisms of drug toxicity. Co-founder of SACTRC for agrochemical poisoning and snakebite research Chair of Australian Therapeutic Guidelines - Toxicology writing group Editorial roles in Clinical Toxicology, Drug Safety, and Australian Prescriber Research Interests include toxicovigilance, epidemiology of poisoning, acute kidney injury in poisoning/snakebite, pesticide safety interventions, antidote development, and pharmacoepidemiology of psychotropic drugs. His work combines clinical trials, population surveillance, and translational research. Scientific Contributions span 440+ peer-reviewed articles and 22 book chapters, with continuous funding since 2002. He has supervised over 20 higher degree students and leads international collaborations in low-and-middle-income countries through NIHR RIGHT4. Key Affiliations : Member of Charles Perkins Centre, Australian Medicines Handbook Editorial Advisory Board, and NIHR RIGHT4 programme.
Dr. Matthias Winter is a Senior Lecturer in the Department of Mathematics at Brunel University's College of Engineering, Design and Physical Sciences. He has been affiliated with Brunel since 2005, following academic positions at the University of Stuttgart (1996-2005) and postdoctoral fellowships at the Institute for Advanced Study in Princeton (1993-94) and Heriot-Watt University in Edinburgh (1994-96). His educational background includes a PhD from Stuttgart University in 1993 and a Habilitation from the same institution in 2003. Dr. Winter's research focuses on mathematical biology, particularly pattern formation in biological systems through reaction-diffusion equations. His work examines spike solutions, pattern formation mechanisms, and the mathematical analysis of biological phenomena. He has made significant contributions to understanding stable spike clusters in various contexts including the Gierer-Meinhardt system. His research spans Mathematical Biology, Pattern Formation, Reaction-Diffusion Systems, Nonlinear Partial Differential Equations, and several related mathematical disciplines. His recent publications (2023-2025) demonstrate continued activity across diverse applications including cancer modeling, ecological systems, climate modeling, and fundamental mathematical analysis of reaction-diffusion phenomena, showing his ability to apply sophisticated mathematical techniques to real-world biological problems. Editorial Board, ISRN Mathematical Analysis, since 2010 Academic Appeals Committee, since 2013 Level One Coordinator for Mathematics, since 2013 Course Director MSc Programme Computational Mathematics with Modelling Mathematics, 2008-2010 Dr. Winter teaches various mathematics courses including Mathematics and Statistics for Economists, Vector Calculus, and Group Projects in Mathematics, with a teaching portfolio spanning from foundational courses to specialized topics related to his research interests.
Professor Guy Williams is a leading academic at the University of Cambridge with a focus on imaging science and clinical neurosciences, affiliated with Downing College and the Wolfson Brain Imaging Centre . Holding a PhD in Physics from his initial Natural Sciences degree, he specializes in nuclear magnetic resonance (NMR) and MRI techniques for brain imaging. Education: BA, PhD in Physics His research centers on non-invasive imaging of brain structure and function, particularly in traumatic brain injury (TBI) and dementia. His work involves developing novel MRI pulse sequences and advanced data analysis algorithms, including AI-based diagnostic tools. He leads studies on white matter integrity post-trauma, longitudinal dementia assessment, and applications of MRI in disorders of consciousness and addiction. Recent publications highlight collaborations in traumatic brain injury outcomes, AI-guided dementia prediction, and neuroimaging of post-COVID cognitive deficits. His team's work on ultra-high field laminar fMRI and distortion correction methods has advanced clinical neuroscience applications. Key techniques include diffusion tensor imaging (DTI), 7 Tesla MRI, and positron emission tomography (PET/MR). His research spans from basic NMR physics to clinical translation, with a strong emphasis on multi-site studies and real-world diagnostic implementation.
Prof. Veronika Somoza is a leading academic in Nutritional Systems Biology, currently affiliated with the University of Vienna and Technical University of Munich (TUM). She holds a professorship in Molecular Food Science and has led key research groups such as the Institute of Physiological Chemistry and the Christian Doppler Laboratory for Bioactive Aromatics. Her career includes roles at institutions like the German Research Institute for Food Chemistry (Garching) and the University of Wisconsin-Madison. Education: Diplom (Justus Liebig University Giessen, 1991), PhD (University of Vienna, 1995), Habilitation (Kiel University, 2002) Research Focus: Bioactive food compounds, flavor chemistry, taste receptor signaling, and gastrointestinal physiology Her work bridges food science and human health, particularly in understanding how food ingredients influence digestion, inflammation, and disease. Notable contributions include discoveries on bitter peptide effects on gastric acid secretion and flavor perception modulation. Awards: FEMA Excellence in Flavor Science (2016), ACS AGFD Fellow (2020), Hans Adolf Krebs Prize (2004) Prof. Somoza has pioneered methodologies in atomic force microscopy for foodborne virus detection and developed bitterness-masking compounds for pharmaceuticals. Her interdisciplinary approach integrates nanobiophysics with nutrition to advance functional food design and clinical applications.
Todd A. Alonzo is a Professor of Research in the Department of Preventive Medicine at the University of Southern California . As Group Statistician for the Children's Oncology Group , he focuses on statistical methods for biomarker analysis, medical diagnostic testing, and clinical trial design in pediatric acute myeloid leukemia (AML). Education: B.S. in Statistics, California State Polytechnic University (1994) MS and PhD in Biostatistics, University of Washington (1997, 2000) Research Interests include: Development of statistical frameworks for diagnostic accuracy Genomic and proteomic profiling in AML Pharmacogenomic score systems for chemotherapy response Non-inferiority trial design in low-event-rate settings Health disparities in pediatric oncology Scientific Awards : Fellow, American Statistical Association (2018) Outstanding Teacher Award, International Society for Magnetic Resonance in Medicine (2017) NIH Predoctoral Cardiovascular Biostatistics Training Grant (1995) ENAR Biometrics Society Distinguished Student Paper Award (1999) WNAR Biometrics Society Best Student Oral Presentation (1999) Leadership & Service includes editorial board memberships (Biometrics, Pediatric Blood & Cancer, Biometrical Journal), reviewer for 30+ scientific journals, and roles on multiple Data Safety and Monitoring Boards. He served as President of the International Biometric Society Western Northern America Region (WNAR) in 2009.
John F. Rudge is a Professor of Geodynamics at the Bullard Laboratories, Department of Earth Sciences, University of Cambridge , and a Fellow and Dean of Trinity College. His research focuses on the dynamics of Earth's interior, including mantle convection, magma transport, and the geochemical evolution of the planet. He employs continuum mechanics, numerical analysis, and statistical methods to address questions about melt dynamics, mantle heterogeneity, and the surface expressions of geophysical processes. Education includes a mathematics undergraduate degree and a PhD in Earth Sciences and Applied Mathematics from Cambridge. He held postdoctoral positions at institutions like ETH Zürich, Yale, and Columbia University before joining Cambridge as a University Lecturer in 2010 and being promoted to Professor in 2022. Key research areas include: Transport of melts and volatiles in the mantle Evolution of Earth's interior from accretion to present Dynamic topography and inner core dynamics Publications span over two decades, with recent works addressing melt rheology, mantle mineralogy, and interdisciplinary applications in oncology. He has supervised numerous PhD students and postdocs, including David Rees Jones, Isarapong Eksinchol, and Laura Alisic. Awards include the Philip Leverhulme Prize and Geological Society President’s Award. Teaching responsibilities include courses on geophysics, magma dynamics, and supervisions in Natural Sciences at Trinity College. Research tools include finite element modeling and collaborations with computational scientists.
University of North Carolina at Chapel HillUnited States
Juliane Nguyen, PhD, is a Professor in the Department of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. She serves as Vice Chair and Director of Graduate Admissions in her department and holds an adjunct appointment as Professor of Biomedical Engineering. Dr. Nguyen is also a member of the UNC Lineberger Comprehensive Cancer Center, where she applies molecular engineering approaches to develop innovative therapeutic solutions. Dr. Nguyen's research focuses on molecular engineering to advance protein-based therapeutics, live biotherapeutics (including engineered probiotic yeast), and extracellular vesicles. Her lab develops cutting-edge technologies to treat diverse conditions including cancer, myocardial infarction, chemotherapy-induced cardiotoxicity, and inflammatory bowel diseases. Her interdisciplinary approach integrates molecular engineering, pharmaceutical sciences, and bioinformatics to create complex biologics with exceptional safety and efficacy profiles. Key research areas include developing therapeutics for cardiac repair, genetically encoded materials targeting tumor-associated macrophages, live biotherapeutics for inflammatory bowel diseases using engineered probiotic yeast, and auxetic patches for dynamic organ repair. Analysis of Dr. Nguyen's recent publications reveals a strong focus on translational research with significant contributions to cardiac repair technologies, cancer immunotherapy, inflammatory bowel disease treatments, and advanced biomaterials. Her work consistently bridges fundamental molecular engineering with clinical applications, particularly in the areas of targeted drug delivery, extracellular vesicle therapeutics, and engineered live biotherapeutics. The research demonstrates a clear trajectory toward developing clinically viable solutions for previously challenging medical conditions. Dr. Nguyen has received numerous prestigious awards and honors including the NSF CAREER Award (2018), Eshelman Innovation Award (2020), and recognition as a Fellow of the Controlled Release Society (2023). She was appointed as a Standing Member of the NIH Drug and Biologic Therapeutic Delivery Study Section (2023-2025) and serves as Executive Editor of Advanced Drug Delivery Reviews since 2021. Her Galenus Guest Professorship at ETH Zuerich (2024) and keynotes at major conferences highlight her international recognition in the field. As Director of Graduate Admissions and an active mentor, Dr. Nguyen has advised numerous PhD and Master's students who have co-authored significant publications with her. Her research is supported by competitive grants including the NSF CAREER Award and other NIH-funded projects. The Nguyen Lab maintains strong collaborations across disciplines, particularly with cardiology, oncology, and biomedical engineering researchers. She leads an interdisciplinary team focused on translating molecular engineering breakthroughs into clinically impactful therapies. The Nguyen Lab operates as a dynamic, interdisciplinary research environment combining expertise in molecular engineering, pharmaceutical sciences, and bioinformatics. The lab's mission is to revolutionize medicine by developing next-generation therapeutics that target diseases at the molecular level. Current projects focus on translating cutting-edge research into life-changing therapies for patients suffering from cancer, myocardial infarction, colitis, and other challenging conditions. The lab's innovative approach to biomolecular engineering positions it at the forefront of developing safe, effective, and personalized therapeutic solutions.
Professor Ali Gilles Tchenguise Miserez holds a joint appointment as Professor in the School of Materials Science and Engineering and the School of Biological Sciences at Nanyang Technological University (NTU) in Singapore. He is also the President's Chair in Materials Science and Engineering. His research group, the Biological and Biomimetic Materials Laboratory (BBML), is highly interdisciplinary, bringing together molecular biologists, chemists, bio-physicists, and materials scientists to study natural materials with unique properties not found in man-made materials. Prof. Miserez's research interests span multiple areas including bioelastomeric membranes & coiled-coil engineering, mechanisms of biofouling adhesion & anti-adhesive coatings, molecular biomimetics of non-mineralized hard tissues, biomineralized structures with graded properties, and liquid-liquid phase separation. His work focuses on understanding the molecular, physico-chemical, and structural principles of biological materials and translating these designs into novel biomimetic synthesis strategies. His laboratory emphasizes "green chemistry" approaches that mimic nature's energy-efficient synthesis methods under ambient conditions. Prof. Miserez's publication record demonstrates significant impact across multiple disciplines, with work appearing in top journals including Science, Nature Materials, Nature Biotechnology, Nature Chemical Biology, and Advanced Materials. His recent research has particularly focused on peptide coacervates for intracellular delivery of therapeutics, with applications in cancer treatment, mRNA delivery, and nucleic acid therapeutics. This work represents a convergence of materials science, biochemistry, and medicine with significant translational potential. Singapore National Research Foundation (NRF) Fellowship (2011) - $3 Million individual research grant for early career scientists Prof. Miserez has mentored numerous PhD students and postdoctoral researchers, many of whom have gone on to successful careers in academia and industry. His laboratory has developed strong international collaborations and has secured significant research funding. Current projects include developing peptide-based delivery systems for cancer therapeutics, understanding marine biofouling mechanisms, and creating biomimetic materials inspired by natural systems. The BBML laboratory is actively recruiting talented researchers interested in interdisciplinary work at the interface of biology and materials science.
Dr. Vikas Srivastava is an Associate Professor of Engineering and Director of the Graduate Program in Biomedical Engineering at Brown University's School of Engineering. His research focuses on solid mechanics, continuum biomechanics, and cell mechanics, with applications in materials under extreme environments and biomedical science. He leads the Srivastava Lab for Solid Mechanics and Biomechanics, which integrates computational models with experimental techniques to address interdisciplinary challenges. Dr. Srivastava holds a Ph.D. in Mechanical Engineering from MIT (2010) and previously held senior roles at ExxonMobil, including leadership in materials mechanics and deepwater drilling engineering. His academic career at Brown began in 2018, during which he has directed over 15 graduate students and secured notable funding. His research interests span mechanobiology, hydrogel-based drug delivery systems, AI-driven predictive modeling, and biomaterial innovations for cancer therapies. He has pioneered physics-informed neural networks for material characterization and developed novel hydrogels to enhance chemotherapy efficacy. Recent articles highlight advancements in polymer fracture modeling, machine learning for non-destructive evaluation, and predictive epidemiological modeling for pandemics. Dr. Srivastava has received the Dean’s Award in Bioengineering and was promoted to tenured Associate Professor in 2023. He actively mentors students through grants like the NSF Graduate Research Fellowship and leads initiatives in biomedical technology translation. The Srivastava Lab collaborates extensively across engineering, biology, and medicine to advance translational research in materials science and clinical applications.
Memorial Sloan Kettering Cancer CenterUnited States
Monica N. Fornier is a physician scientist at Memorial Sloan Kettering Cancer Center (MSK) specializing in breast medical oncology . With a clinical focus on improving outcomes for breast cancer patients, she has particular expertise in bone health related to cancer therapies. Fluent in English, Italian, and French, Dr. Fornier treats international patients and contributes to multidisciplinary care teams. Education: MD from University of Milan (Italy), residency and fellowship at University Hospital of Milan and MSK Certifications: Board-certified in Internal Medicine and Medical Oncology (Europe) Her research spans neoadjuvant endocrine therapy , bone loss prevention in cancer patients, and HER2-positive breast cancer treatment beyond trastuzumab. Recent publications address ER+/HER2- breast cancer immune responses, alopecia management in survivors, and regulatory T cell mechanisms . Dr. Fornier has received multiple Castle Connolly Top Doctor awards (2023-2025) and participates in MSK clinical trials for novel cancer treatments.
